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Background: Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features,
prognostic factors, patterns of failure, and treatment outcomes.
Patients and methods: A retrospective international study of 204 eligible patients presenting to the International
Extranodal Lymphoma Study Group-affiliated institutions from 1980 to 2003.
Results: Median age was 64 years, with 95% of patients presenting with unilateral disease. Median overall survival
(OS) was 8.0 years, and median progression-free survival 5.5 years. In multifactor analysis, favourable International
Prognostic Index score, anthracycline-containing chemotherapy, and radiotherapy (RT) were significantly associated
with longer OS (each P £ 0.03). There was no benefit from mastectomy, as opposed to biopsy or lumpectomy only. At
a median follow-up time of 5.5 years, 37% of patients had progressed—16% in the same or contralateral breast, 5% in
the central nervous system, and 14% in other extranodal sites.
Conclusions: The combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT
produced the best outcome in the pre-rituximab era. A prospective trial on the basis of these results should be
pursued to confirm these observations and to determine whether the impact of rituximab on the patterns of relapse
and outcome parallels that of DLBCL presenting at other sites.
Key words: anthracycline-based chemotherapy, breast, large B-cell lymphoma, radiotherapy
introduction
Extranodal presentations of non-Hodgkin’s lymphoma (NHL)
are increasingly frequent, with an estimated 40%–50% of
patients with stage I/II NHL having extranodal disease.
However, breast is an uncommon primary site, comprising
only 2% of localized extranodal NHL presentations. Only a few
hundred cases have been reported, most in small retrospective
series [1–14], with only one prospective study identified [15].
This paucity of case material has clouded the prognosis and
patterns of failure for patients with primary breast NHL, with
wide variations in outcomes, and prognostic factors, reported,
e.g. 5-year survival figures ranging from 26% to 66% in larger
series [2, 3, 9, 10, 12]. Certain common themes have
emerged—diffuse large B-cell histology predominates,
prognosis poorer than anticipated by stage, significant risk of
contralateral breast involvement, and tendency to central
nervous system (CNS) relapse. But are these themes real or the
result of reporting bias and statistical variability?
In an attempt to more precisely define the specific features
and outcomes of primary breast NHL, the International
Extranodal Lymphoma Study Group (IELSG) has conducted
a large retrospective study, aiming to incorporate the results
into the design of a subsequent prospective study.
design and methods
Data on all cases of primary breast NHL presenting to participating
institutions from January 1980 to December 2003 were collected
retrospectively. Study eligibility required confirmed histological diagnosis
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and disease localized to one or both breasts 6 regional nodes. Patients
presenting with either systemic disease with breast involvement or recurrent
lymphoma in the breast following prior treatment were excluded. Various
histological classifications were in use throughout the study period, and
patients classified according to Kiel, Working Formulation, Revised
European-American Lymphoma, or World Health Organization (WHO)
were all eligible. Wherever possible, central pathology review was
undertaken, and all cases were reclassified according to the WHO
classification. This report is confined to the 204 cases with WHO
(re)classification as diffuse large B-cell lymphoma (DLBCL) and adequate
data.
Study-specific case record forms (CRFs) were provided. Collected data
included patient and tumour characteristics, diagnostic test results,
treatment parameters, and clinical outcomes. As this was a retrospective
study, staging procedures were not standardized, and not all variables were
available for each patient. Patients were staged according to the Ann Arbor
classification [16], and the International Prognostic Index (IPI) score
was determined according to published criteria [17]. The Ann Arbor
staging of extranodal NHL involving bilateral paired organs remains
contentious, but for this study, patients with bilateral disease were
considered stage IV. CRFs were entered into one of two databases, which
were merged for analysis.
Response was assessed after completion of planned initial therapy
according to WHO response criteria [18]. All outcomes were calculated
from treatment start date to date of the stated events—overall survival (OS)
to death from any cause, progression-free survival (PFS) to disease
progression, relapse or death from any cause, and cause-specific survival
(CSS) to death from disease or treatment-related causes.
The median follow-up time, computed by the reverse Kaplan–Meier
method [19], was 5.5 years. Log-rank and Cox regression methods were
used to analyse time-to-event data. The exact log-rank test was used to
carry out an unadjusted comparison between two groups; this test is on the
basis of the exact distribution of the sum of independent hypergeometric
random variables. For comparisons between more than two groups, the
Mantel–Cox log-rank test was used, and a test for trend was carried out
when the subgroups consisted of ordered categories; these tests are based
on the approximation to the chi-square distribution. Competing risks
analysis using the method of Kalbfleisch and Prentice [20] was used to
estimate cumulative incidence of first progression at each predominant
site (breast, regional nodes, CNS, and other sites). Correlations among
potential prognostic factors were examined using the Fisher’s exact test for
2 · 2 tables; otherwise, a test for trend was used when any subgroups
consisted of ordered categories. Two-sided tests were used throughout.
P values of <0.05 were considered statistically significant. Given the
exploratory and hypothesis-generating nature of the study, no formal
adjustment for multiple comparisons was made. Analyses were carried out
using S-PLUS [21] and SPSS [22] software.
results
patient characteristics
Table 1 documents baseline characteristics of the patient group.
Ten patients were reported as having mixed histology, with
a mucosal-associated lymphoid tissue component plus
predominant DLBCL. The outcome for these patients was
similar to the remainder of the cohort, and they are included in
all further analyses.
The median age was 64 years (range 15–89 years), with all but
five patients (2%) female. Performance status was 0 or 1 in 89%
of patients. The median tumour size was 4.0 cm (range 1–20
Table 1. Patient characteristics at presentation
No. %
Diagnosis (WHO classification)
DLBCL 194 95
DLBCL + MALT 10 5
Age at treatment start date (years)
<60 81 40
60–69 53 26
‡70 70 34
ECOG performance status at presentation
0 129 63
1 53 26
2 10 5
3 2 1
Unknown 10 5
B symptoms
Absent 195 96
Present 9 4
Primary site of lymphoma
Right breast 104 51
Left breast 87 43
Both breasts 11 5
Single breast, side unknown 2 1
Size of primary tumour (cm)a (% of 190)
<4.0 72 38
4.0–6.9 68 36
‡7.0 50 26
Nodal sites involvement at diagnosis
None 145 71
Axillary 51 25
Supraclavicular 6 axillary 7 3
Other 1 <1
Patient pregnant at diagnosis
No 204 100
Patient lactating at diagnosis
No 198 97
Yes 1 <1
Not applicable 5 2
Ann Arbor stage
IE unilateral 137 67
IIE unilateral 56 27
IVE bilateral 11 5
Lactate dehydrogenase
Elevated 39 19
Normal 114 56
Unknown 51 25
IPIb
0 54 26
1 75 37
2 30 15
3 7 3
Unknown 38 19
aFor bilateral cases, this is the larger value of the left and right breast
diameters.
bIPI was derived from the individual contributing data items if all available;
otherwise, the score recorded on the case record form was used.
WHO, World Health Organization; DLBCL, diffuse large B-cell lymphoma;
MALT, mucosal-associated lymphoid tissue; ECOG, Eastern Cooperative
Oncology Group; IPI, International Prognostic Index.
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cm), with regional nodal involvement in 29%. Bilateral breast
involvement was present in 5% of patients at presentation.
Fine-needle aspiration cytology was carried out before formal
biopsy in 80 patients (39%), and was diagnostic of DLBCL in
52 patients (65%). Histology was reviewed centrally in 60
patients (29%), with a concordance rate of 95% with the local
diagnosis. Patients with reviewed histology other than
DLBCL were excluded from further analyses.
treatment and outcome
First-line therapy is documented in Table 2.
Treatment was at the discretion of the individual physician,
with both single-modality and combination therapies used.
Systemic chemotherapy (6 surgery) was given to 80% of
patients, with 87% of regimens containing an anthracycline. Of
those who received chemotherapy, 62% also received RT. Only
eight patients received intrathecal chemotherapy as CNS
prophylaxis.
A complete response to first-line therapy was achieved in
89% of patients, partial response in 4%, and progressive disease
in 4% (n = 8, including three with bilateral presentation).
Three percent of patients were unassessable, mainly due to
early death from intercurrent disease.
Before proceeding with further outcome analyses, survival
curves of patients who had central pathology review were
compared with those whose pathology had not been reviewed.
No significant difference in OS (P = 0.90) or PFS (P = 1.0) for
the two groups was demonstrated. An apparent minor
divergence in CSS after 5 years in favour of patients who had
not had central pathology review almost certainly related to the
small number of events rather than to a real difference. It was
therefore considered appropriate to combine the two groups
for subsequent analyses.
Median OS was 8.0 years [95% confidence interval (CI)
6.5–10.9 years], with 5- and 10-year OS rates 63% (95% CI
55% to 70%) and 47% (95% CI 38% to 56%), respectively
(Figure 1). The median PFS was 5.5 years (95% CI 3.7–8.0
years), with median CSS not reached at the time of analysis.
At a median follow-up time of 5.5 years, there were
76 progression events (37% of patients) and 81 deaths, with
54 deaths (26% of all patients) attributable to progressive
lymphoma and/or treatment-related toxicity. Only one possible
case of treatment-related second malignancy was identified,
a patient who developed squamous cell carcinoma of the
cervical oesophagus, within the RT field. Although the rate of
progression and lymphoma-related death was highest in the
first 3 years, there was a continuing pattern of progression and
death up to 14 years from initial treatment. All ipsilateral
progression events occurred within 2.6 years from
commencement of treatment, whereas contralateral breast
progressions occurred up to 13.3 years. Median OS following
progression after first-line therapy was 1.0 years (95% CI
0.7–2.1 years), with 20% of patients with relapsed disease
estimated to be alive at 5 years and 11% at 10 years after
progression.
In the 11 patients with synchronous bilateral presentation,
there were seven progressions during or following first-line
therapy, with six deaths, all due to progressive disease, and all
within 3 years of initial treatment (3-year PFS 36% and OS
46%). Only one patient developed first progression in CNS.
The median PFS for this group was 1.3 years and the median
OS 2.4 years, with wide CIs reflecting the small number of
patients. In comparison to unilateral presentation, the hazard
ratio (HR) for progression was 1.6 (P = 0.22) and for death
was 1.9 (P = 0.15).
The outcome for males did not appear to differ from the
remainder of the cohort, with 5-year OS of 60%, although the
CIs were wide, given the small number of patients.
prognostic factor analysis and patterns of relapse
Unifactor and multifactor analyses of potential prognostic
factors were carried out for all events (Table 3). A number of
confounding associations were identified, e.g. use of
anthracycline negatively related to age and positively to nodal
involvement, RT negatively related to age and IPI, thus only the
more informative multifactor analyses are presented. The
prognostic factors that retained statistical significance for OS
were IPI (P < 0.001), anthracycline-containing chemotherapy
(P = 0.02), and RT (P = 0.03). For PFS, significant prognostic
factors were IPI (P = 0.01) and anthracycline-containing
chemotherapy (P = 0.001). For CSS, IPI was once again
significant (P = 0.002). There was a negative association of all
outcome measures with the extent of surgery, with patients who
underwent radical mastectomy having a statistically
significantly poorer CSS (P = 0.03). Although a greater number
of cycles of any systemic chemotherapy (>3 cycles) was
associated with an improved CSS (P = 0.04), for those patients
receiving anthracycline-containing chemotherapy, this
significance was lost, i.e. the importance of receiving
anthracycline appeared to diminish the significance of the
number of cycles of chemotherapy, as was also the case for
OS and PFS. Other factors not found to have prognostic
significance in multifactor analysis included presence of B
symptoms, tumour diameter, nodal involvement, and
treatment era. Bilaterality was not statistically significant on
unifactor analysis, and was therefore included in multifactor
analyses only as a component of IPI.
Figure 2 demonstrates the impact of anthracycline-
containing chemotherapy on OS. Patients who received
anthracycline had an OS of 73% at 5 years and 58% at 10 years.
Survival curves for all patients who received anthracycline-
containing chemotherapy and/or RT are shown in Figure 3.
The combination of chemotherapy and RT was associated with
the best outcomes (P = 0.001).
Seventy-six patients (37%) developed progression following
first-line therapy, with 18 patients having ‡2 sites of
involvement at first progression. Breast was a site of first
progression in 32 patients, regional nodes in 13, CNS in 11,
other extranodal sites in 28, other nodal sites in 11, and bone
marrow in two (sites unknown in five). Table 4 documents
the cumulative incidence of progression at each predominant
site.
In the 191 cases with unilateral presentation and known
laterality, breast was the first site of progression in 28. Nine of
these progressions were ipsilateral, with 19 in the contralateral
breast. RT substantially reduced the risk of ipsilateral
progression (HR RT : no RT = 0.4, P = 0.29). Given the small
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number of ipsilateral breast progressions in the group who
received RT, no dose relationship was explored. There was
a trend in reduction of risk of locoregional progression with
increasing extent of RT fields (0.021). However, due to the
small number of nodal recurrences, no conclusion could be
drawn regarding the benefit of stage I patients undergoing
prophylactic nodal RT.
Anthracycline-containing chemotherapy appeared to reduce
the risk of contralateral breast progression. The HR for
anthracycline-containing chemotherapy compared with
non-anthracycline-containing chemotherapy was 0.2 (P = 0.028).
There was no evidence that RT to the involved breast reduced
the risk of contralateral progression. OS following first
progression in breast was similar whether the progression was
Table 2. First-line therapy
No. %
Year of commencement of first-line therapy 1980–1989 40 20
1990–1995 54 26
1996–1999 71 35
2000–2003 39 19
Treatment Surgery only 11 5
RT only 14 7
SC only 31 15
S + RT 15 7
S + SCa 32 16
RT + SCb 59 29
S + RT + SCc 42 21
Any surgery 100 49
Any RT 130 64
Any SC 164 80
Surgery
Type of surgery, excluding biopsy only
(% of 100)
Simple mastectomy 9 9
Modified/radical mastectomy 30 30
Lumpectomy 6 axillary dissection 58 58
Axillary dissection 1 1
Unknown 2 2
SC
No. of patients No. of cycles
1–2 3–4 5–6 ‡6 Unknown
Anthracycline containing 143 6 64 64 7 2
No anthracycline 20 6 7 5 1 1
Regimen unknown 1 – – – – 1
Total 164 12 71 69 8 4
RT
Fields (n = 130) Initially involved breast only 65 50
Initially involved breast and regional lymph
nodes
45 35
Ipsilateral axillary nodes only 2 2
Chest wall only 2 2
Both breasts 6 regional nodes
(bilateral presentation)
5 4
RT fields unknown 11 8
RT dose (ipsilateral breast, n = 110) Median 40 Gy
Range 4–60 Gy
Distribution
<30 Gy 4 4
30–39.9 Gy 34 31
40–49.9 Gy 61 55
‡50 Gy 11 10
aIntrathecal chemotherapy, one patient.
bIntrathecal chemotherapy, five patients.
cIntrathecal chemotherapy, two patients.
S, surgery; RT, radiotherapy; SC, systemic chemotherapy.
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ipsilateral or contralateral, with 22% and 30%, respectively,
alive at 5 years after progression (P = 0.62).
Breast was the first site of progression in four of the patients
with bilateral breast involvement at presentation. All were dead
within 12.5 months of progression.
CNS was the first site of progression in 11 patients (5%).
There were no CNS progressions in the eight patients who
received prophylactic intrathecal chemotherapy (P = 1.0).
Given the small number of events, no prognostic factors for
CNS progression could be identified.
discussion
The literature of primary breast NHL comprises many small
retrospective series and just one prospective study, with
inconsistent conclusions drawn, from breast being a site of
presentation with a very poor prognosis, through to a prognosis
no different from a similarly staged nodal presentation of
DLBCL. This large multicentre study has the potential flaws of
all retrospective studies, but nevertheless provides strong
evidence that primary DLBCL of the breast is a distinct entity,
with characteristic patterns of relapse differing from those of
nodal DLBCL.
The Eastern Cooperative Oncology Group (ECOG) study
1484 [23] and the Southwest Oncology Group (SWOG) study
6736 [24, 25] established expected outcomes for patients with
early stage DLBCL treated with anthracycline-containing
chemotherapy (CHOP: cyclophosphamide, adriamycin,
vincristine, prednisolone) 6 RT. The studies differed in
eligibility criteria and treatment assignment, but included both
nodal and extranodal stage I–II DLBCL. The 10-year survival
outcomes for our entire cohort of patients with primary breast
DLBCL are considerably inferior to those reported in the
ECOG and SWOG studies. However, some of our patient
group had undoubtedly been treated suboptimally. When the
comparison is restricted to those of our patients who received
anthracycline-containing systemic chemotherapy, the
inferiority of outcome is reduced; and in those patients treated
with anthracycline-containing chemotherapy and RT, similar
outcomes are achieved. The small group of patients with
synchronous bilateral disease appears to be an exception, with
substantial though non-significant increases in risk of early
progression and poorer survival irrespective of treatment
programme. The decision to regard such presentations as stage
IV appears vindicated by the study data.
Sites of progression were predominantly extranodal in our
patients, with the contralateral-paired organ at high risk,
a phenomenon similarly described in primary testicular DLBCL
[26, 27]. Contralateral progression was more common in
this series than ipsilateral, the rate of ipsilateral progression
having been substantially reduced by the use of RT in most
patients. The role of prophylactic nodal irradiation remains
unproven. One unexpected finding was that the risk of CNS
relapse was relatively low, occurring in only 5% of patients.
This is at variance with the reports of other smaller studies, and
is considerably lower than the risk seen in primary testicular
DLBCL [27]. It may be that primary breast DLBCL does not
have the same tropism for CNS as does testicular DLBCL, and
that this difference explains the generally superior survival
for patients with primary breast DLBCL compared with that of
patients with primary testicular DLBCL. However, it is possible
that limiting the eligibility to patients with localized disease
has led to underestimation of the rate of CNS involvement.
We must regard this result with caution.
The discriminating ability of the IPI in patients with primary
disease in breast has been validated in our study population.
The IPI was a significant prognostic factor for OS, PFS, and
CSS. The inclusion of an anthracycline in the chemotherapy
regimen was, as expected, another important predictor of
outcome, being significant for both OS and PFS. One factor
found not to have prognostic significance was the extent of
surgery—OS and PFS were not improved with more extensive
surgery, and radical mastectomy was actually associated with
poorer CSS. This finding has been described in other series, and
although it may be a statistical quirk, it is possible that
extensive surgery delayed the commencement of chemotherapy,
with detrimental outcome.
The delivery of RT was a statistically significant predictor of
improved OS in this study, and was associated with non-
significant improvements in PFS, CSS, and risk of ipsilateral
locoregional progression. Comparisons of survival outcomes
by treatment type showed a statistically significant benefit
resulting from the addition of RT to systemic chemotherapy,
including those patients receiving anthracycline-containing
regimens, and this benefit persisted with long-term follow-up.
RT resulting in an improvement in PFS would not be an
unexpected finding in patients with DLBCL, but the significant
sustained survival benefit seen in the study population is at
variance with many reported series of similarly staged
predominantly nodal DLBCL. Two large prospective studies
undertaken by the Groupe d’Etude des Lymphomes de l’Adulte
(GELA) [28, 29] concluded that the addition of RT to
anthracycline-containing chemotherapy did not result in
a survival benefit, and was possibly detrimental to survival,
presumably as a result of late radiation toxicity. However,
radiation to the breast in the modern era can be delivered with
Figure 1. Cause-specific survival (CSS), overall survival (OS), and
progression-free survival (PFS).
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Table 3. Summary table of time-to-event analyses
Analysis PFS OS CSS
Event-free rates (95% CI)
3 years 59% (52–66) 73% (66–79) 80% (73–85)
5 years 54% (46–61) 63% (55–70) 71% (63–78)
10 years 39% (31–48) 47% (38–56) 63% (53–72)
Multifactor analysesa
Number of events 71 54 37
Treatment era
Hazard ratio (per category increaseb) 0.9 1.0 0.9
95% CI (0.7–1.3) (0.7–1.4) (0.6–1.4)
P 0.59 0.98 0.63
International Prognostic Index
Hazard ratio (per unit increase) 1.4 2.0 1.9
95% CI (1.1–1.9) (1.4–2.7) (1.3–2.8)
P 0.01 <0.001 0.002
Anthracycline given
Hazard ratio 0.4 0.5 0.7
95% CI (0.3–0.7) (0.3–0.9) (0.3–1.6)
P 0.001 0.02 0.38
Radiotherapy given
Hazard ratio 0.7 0.5 0.6
95% CI (0.4–1.1) (0.3–1.0) (0.3–1.2)
P 0.12 0.03 0.15
Radical mastectomy carried out
Hazard ratio 1.6 1.7 2.4
95% CI (0.9–2.8) (0.9–3.2) (1.2–4.8)
P 0.13 0.11 0.03
Central pathology review
Hazard ratio 1.5 1.7 2.4
95% CI (0.9–2.6) (0.9–3.1) (1.2–4.8)
P 0.11 0.10 0.02
Cycles of systemic chemotherapy >3
Hazard ratio 0.6 0.8 0.5
95% CI (0.4–1.1) (0.4–1.6) (0.2–0.9)
P 0.13 0.50 0.04
Nodal involvement
Hazard ratio 1.2 1.0 0.7
95% CI (0.7–2.1) (0.5–1.9) (0.3–1.9)
P 0.55 0.88 0.58
DLBCL (no MALT component)
Hazard ratio 1.6 1.6 1.0
95% CI (0.5–5.1) (0.4–6.7) (0.2–4.5)
P 0.42 0.49 0.98
Primary tumour size
Hazard ratio (per category increasec) 1.1 1.2 1.2
95% CI (0.8–1.5) (0.8–1.7) (0.8–1.9)
P 0.61 0.33 0.41
aResults from multifactor analyses were on the basis of 154 cases with no missing data on any of the factors examined. For the factors that were statistically
significant following multifactor analysis, the adjusted hazard ratio and P value are presented, that is, adjusting for the significance of each other. For the
factors that were not statistically significant following multifactor analysis, the hazard ratio and P value after adjusting for the significant factors are presented.
bTreatment era categories: 1980–1989, 1990–1995, and 1996–2003.
cPrimary tumour size categories: <4, 4–6.9, and ‡7.0 cm.
PFS, progression-free survival; OS, overall survival; CSS, cause-specific survival; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; MALT,
mucosal-associated lymphoid tissue.
Statistically significant results are indicated in bold type.
original article Annals of Oncology
238 | Ryan et al. Volume 19 | No. 2 | February 2008
modest acute and late toxicity, and in such a situation, the
potential for a positive benefit is substantially increased. Thus,
the concept of RT improving survival in primary DLBCL of
the breast is not necessarily inconsistent with the GELA and
other studies, and is deserving of further study.
The use of immunohistochemistry to assist in the
classification and prognostication of lymphoma is now
standard. Molecular analysis techniques using DNA
microarrays are also becoming more common, facilitating
identification of different molecular ‘signatures’ in lymphomas
with identical morphology. Recent studies looking specifically
at immunohistochemistry of primary breast DLBCL [30–32]
have identified a number of different cytogenetic patterns with
apparent prognostic implications. Immunohistochemical
and molecular analyses of the cases submitted for central
review are ongoing, and will provide further insights into the
nature of primary breast DLBCL. These analyses will be the
subject of a separate report.
In any retrospective study, accuracy and completeness of data
may not be ideal, and controlling for all factors influencing
outcome may have been imperfect in some analyses. Although
the study results are consistent with our original hypothesis
that primary breast DLBCL is intrinsically different from
DLBCL presenting at other sites, the conclusions must be
regarded as suggestive only, rather than definitive. On the basis
of our study results, we conclude that the outcomes for patients
with early stage primary breast DLBCL treated with optimal
therapy are similar to those of nodal presentations of DLBCL.
Recommended standard therapy for inclusion in future studies
is limited surgery/biopsy, followed by ‡3 cycles of
anthracycline-containing chemotherapy and RT to the
ipsilateral breast 6 regional nodes. CNS prophylaxis does not
appear to be indicated routinely. Patients presenting with
bilateral disease appear to be a poor prognosis group, and
intensification of chemotherapy should be considered.
One final consideration, with a series acquired over a 20-year
period, is how subsequent developments in treatment should
be incorporated into management recommendations.
Anthracycline-containing chemotherapy remains standard, but
the addition of rituximab to chemotherapy has been a major
recent advance, with demonstrated improvement in outcomes
of patients with DLBCL in a variety of sites [33–35]. Primary
breast lymphoma, however, has been poorly represented in
the patient group studied, and it should not be automatically
assumed that the same improvements will be seen in this rare
presentation of DLBCL. Thus, it is important that future
prospective protocols for primary DLBCL of the breast
incorporate rituximab and perhaps other targeted therapies
arising from further research. How these might impact on other
aspects of the treatment protocol will only become apparent
through controlled prospective studies.
Figure 2. Overall survival by anthracycline status.
Figure 3. Overall survival by treatment type (chemotherapy restricted to
anthracycline). RT, radiotherapy; SC, systemic chemotherapy; S, surgery.
Table 4. Cumulative incidence of each predominant site of progression
Progression site No. of casesa Estimated cumulative incidence (6 standard error)
3 years 5 years 10 years
Breast (6 regional nodes, 6 CNS, 6 other sites) 32 14% 6 3% 16% 6 3% 17% 6 3%
Regional nodes (6 CNS, 6 other sites but not breast) 5 2% 6 1% 3% 6 1% 3% 6 1%
CNS (6 other sites but not breast or regional nodes) 9 3% 6 1% 5% 6 2% 6% 6 2%
Sites other than breast, regional nodes or CNSb 25 11% 6 2% 11% 6 2% 16% 6 3%
aProgression sites unknown in five patients.
bOther sites include the following: nodal, four; extranodal, 16 (including one case of spleen); nodal + extranodal, four; marrow, one.
CNS, central nervous system.
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